Bosutinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CIPM (Spain), HAS (France) and HIRA (South Korea), among others, recommended or restricted bosutinib, while AWMSG (Wales) and CONITEC (Brazil) did not recommend it.
On the same population the two systems disagree outright: SMC (Scotland) recorded recommended for “Treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML)…”, while AWMSG (Wales) recorded not recommended for “Treatment of newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukaemia.”.
The file has been open for more than a decade: 12.1 years separate the first record, 2 Aug 2013 at AWMSG (Wales), from the most recent, 24 Sep 2025 at CIPM (Spain).
No assessment is on file from PBAC (Australia) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
Not every gap is a refusal: for bosutinib, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 4 of 16 records date from 2023 or later.
5 distinct indication wordings are recorded for bosutinib by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess bosutinib, on 2 Aug 2013; CIPM (Spain) did not open a file until 24 Sep 2025 — an unusually long tail of 12.1 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 9 years in total.
5 of the 10 agencies here assessed bosutinib more than once, HAS (France) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
10 of the 18 agencies in this archive hold a record for bosutinib.
The full ledger for bosutinib reads 8 recommended, 2 not recommended, 2 no benefit and 1 restricted, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 24 Sep 2025 | Indicación terapéutica autorizada: Bosulif está indicado para el tratamiento de: • Pacientes adultos y pediátricos a par… | financed by the SNS · art. 92 a, c | source |
| NYE METODER (Norway) | 15 Jun 2025 | Behandling av voksne pasienter med nydiagnostisert Philadelphiakromosom-positiv kronisk myelogen leukemi (Ph+ KML) i kro… | introduced | source |
| CONITEC (Brazil) | 29 May 2025 | Tratamento, em 2ª linha, de pacientes adultos com leucemia mieloide crônica com cromossomo Philadelphia positivo (LMC Ph… | not incorporated | source |
| HIRA (South Korea) | 7 Sep 2023 | 필라델피아염색체 양성 만성골수성백혈병 (Ph+ CML) | reimbursable only at the evaluated price | source |
| G-BA (Germany) | 19 Nov 2021 | Bosulif — benefit assessment §35a | added benefit: not proven | source |
11 further decisions for bosutinib, across 6 agencies, are not shown here. They link to 10 further source documents.
Related molecules
- nilotinib — divergent outcome (recommended vs not recommended) on a shared indication
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
Coverage: 16 decisions for bosutinib from 10 agencies, 2013 to 2025. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.